FY2025 EPS Estimates for Kura Oncology, Inc. (NASDAQ:KURA) Reduced by Analyst

Kura Oncology, Inc. (NASDAQ:KURA) – Analysts at HC Wainwright reduced their FY2025 earnings per share estimates for shares of Kura Oncology in a report released on Monday, June 24th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn ($2.96) per share for the year, down from their previous estimate of ($2.83). HC Wainwright currently has a “Buy” rating and a $32.00 price target on the stock. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.56) per share.

A number of other equities analysts also recently weighed in on the company. StockNews.com downgraded Kura Oncology from a “hold” rating to a “sell” rating in a research report on Monday, April 15th. JMP Securities reaffirmed a “market outperform” rating and set a $32.00 target price on shares of Kura Oncology in a research note on Tuesday, June 18th. Finally, Wedbush reissued an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a research note on Friday, May 3rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $28.36.

Kura Oncology Stock Down 0.5 %

Shares of NASDAQ KURA opened at $20.50 on Wednesday. The stock has a market cap of $1.56 billion, a P/E ratio of -9.45 and a beta of 0.94. Kura Oncology has a 52-week low of $7.41 and a 52-week high of $24.17. The firm has a 50 day moving average price of $20.76 and a 200 day moving average price of $19.20. The company has a debt-to-equity ratio of 0.02, a quick ratio of 16.67 and a current ratio of 16.67.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.03). The business’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.50) EPS.

Insider Buying and Selling

In other news, insider Teresa Brophy Bair sold 2,615 shares of the company’s stock in a transaction on Monday, May 20th. The shares were sold at an average price of $22.15, for a total transaction of $57,922.25. Following the transaction, the insider now directly owns 68,979 shares of the company’s stock, valued at approximately $1,527,884.85. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 5.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Kura Oncology

A number of hedge funds have recently added to or reduced their stakes in KURA. Artal Group S.A. grew its holdings in Kura Oncology by 8.6% during the first quarter. Artal Group S.A. now owns 1,919,884 shares of the company’s stock worth $40,951,000 after acquiring an additional 151,828 shares during the period. Price T Rowe Associates Inc. MD grew its position in Kura Oncology by 17.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 20,148 shares of the company’s stock worth $430,000 after purchasing an additional 2,940 shares during the last quarter. Avoro Capital Advisors LLC increased its stake in Kura Oncology by 29.2% in the first quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock valued at $82,120,000 after acquiring an additional 870,000 shares during the period. Affinity Asset Advisors LLC grew its position in Kura Oncology by 281.4% in the first quarter. Affinity Asset Advisors LLC now owns 730,492 shares of the company’s stock valued at $15,581,000 after acquiring an additional 538,957 shares during the period. Finally, Platinum Investment Management Ltd. acquired a new position in Kura Oncology in the first quarter valued at about $998,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.